Brexpiprazole
Back to searchMolecule Structure
Scientific Name
Brexpiprazole
Description of the Drug
Brexpiprazole is a serotonin–dopamine activity modulator used in the treatment of major depressive disorder as an adjunct and schizophrenia.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB09128
http://www.drugbank.ca/drugs/DB09128
Brand Name(s)
Rexulti
Company Owner(s)
Otsuka Pharmaceutical Co Ltd, Teva Pharmaceuticals Usa Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Dopamine D2 receptor | SINGLE PROTEIN | PARTIAL AGONIST | CHEMBL217 |
| Serotonin 1a (5-HT1a) receptor | SINGLE PROTEIN | PARTIAL AGONIST | CHEMBL214 |
| Serotonin 2a (5-HT2a) receptor | SINGLE PROTEIN | ANTAGONIST | CHEMBL224 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL1037592 | |
| PharmGKB | PA166160053 | |
| Human Metabolome Database | HMDB0249379 | |
| DrugBank | DB09128 | |
| PubChem: Thomson Pharma | 17430973 | |
| PubChem | 11978813 | |
| LINCS | LSM-45790 | |
| Nikkaji | J3.002.326I | |
| BindingDB | 194780 | |
| EPA CompTox Dashboard | DTXSID40238527 | |
| DrugCentral | 5014 | |
| ChemicalBook | CB52681994 | |
| Guide to Pharmacology | 7672 | |
| rxnorm | BREXPIPRAZOLE | REXULTI |
| ChEBI | 134716 | |
| ZINC | ZINC000084758479 |
